Why Two People Drinking the Same Olive Oil Get Wildly Different Results
You take the same high-polyphenol EVOO as your friend. Same bottle, same two tablespoons a day. Three months later, their inflammation markers have dropped, their LDL has shifted, and they feel noticeably better. You feel exactly the same as before. Is the oil a fraud? Are they imagining it? A landmark 2024 systematic review in Redox Biology — pooling 153 human clinical studies — finally explains why: your gut microbiome, your genes, your age, and your BMI collectively determine whether olive oil's polyphenols actually reach your bloodstream at therapeutic concentrations, or pass straight through you.
Factors driving the inter-individual variability in the metabolism and bioavailability of (poly)phenolic metabolites: A systematic review of human studies
Favari C, Rinaldi de Alvarenga JF, Sánchez-Martínez L, Tosi N, Mignogna C, Cremonini E, Manach C, Bresciani L, Del Rio D, Mena P.
Redox Biology. 2024 May;71:103095. DOI: 10.1016/j.redox.2024.103095. PMID: 38428187.
The Inconvenient Truth Behind Inconsistent Results
Anyone who has spent time reading the olive oil clinical literature will have noticed something uncomfortable: the effect sizes vary wildly between trials. One RCT shows dramatic reductions in LDL oxidation and CRP. Another, using similar doses and similar participants, shows almost nothing. Critics of the field chalk this up to industry bias, methodological sloppiness, or placebo effects. The real explanation may be more interesting — and more actionable — than any of those.
The assumption underlying most nutritional research is that if you give Person A and Person B the same food in the same quantity, they receive equivalent biological exposure to that food's active compounds. For drugs this is roughly true. For polyphenols — the diverse class of plant compounds that includes olive oil's hydroxytyrosol, oleocanthal, and oleuropein — it is almost certainly wrong. And the degree to which it is wrong, according to Favari et al.'s systematic review, is clinically significant.
The paper doesn't just identify the problem. It maps the landscape of who absorbs what, why, and which biological variables are driving the separation between high absorbers and low absorbers. For anyone making purchasing decisions about high-polyphenol EVOO, this is essential reading.
Advertisement
Study Design: 153 Studies, One Problem
Researchers from the University of Parma's Human Nutrition Unit — one of Europe's leading groups in polyphenol pharmacokinetics — conducted a pre-registered systematic review of human studies that measured polyphenol absorption, distribution, metabolism, and excretion (ADME) and also reported inter-individual variability (IIV) in those outcomes. That second criterion was crucial: most nutrition studies measure average effects and ignore the spread. This review specifically sought out the spread.
Out of thousands of potential studies, 153 met inclusion criteria — each providing human-level data on how polyphenol metabolites varied between participants eating identical amounts of the same foods or supplements. The phenolic sub-classes examined included flavonoids (quercetin, catechins, anthocyanins), phenolic acids, prenylflavonoids, isoflavones, ellagitannins (urolithins), resveratrol, avenanthramides, alkylresorcinols, and — critically for our purposes — hydroxytyrosol, the principal bioactive polyphenol in extra virgin olive oil.
Key Findings: Two Types of People, Two Very Different Olive Oils
The review's central finding is that inter-individual variability in polyphenol metabolism is not random noise — it follows identifiable patterns. Two distinct types of IIV were identified:
Type 1: The High/Low Excretor Gradient
For flavonoids, phenolic acids, alkylresorcinols, and — specifically called out — hydroxytyrosol, the population distributes along a continuous gradient from high excretors (high systemic exposure) to low excretors (minimal systemic exposure). This is not a binary split. It is a spectrum, but the tails are far enough apart to represent meaningfully different biological realities.
What this means practically: two people consuming identical doses of the same high-phenolic EVOO (say, 50 mg/day of hydroxytyrosol equivalents from a 500 mg/kg oil at 50 mL/day) can end up with dramatically different circulating hydroxytyrosol metabolite levels. The high excretor may reach concentrations associated with measurable antioxidant and anti-inflammatory effects. The low excretor may see little to no systemic exposure.
Type 2: Producer vs. Non-Producer (Qualitative)
For other polyphenol classes — ellagitannins (converted to urolithins), isoflavones (converted to equol), and resveratrol (converted to lunularin) — the variation is qualitative rather than quantitative: you either have the right gut bacteria to make the bioactive metabolite, or you don't. This is relevant for olive-adjacent Mediterranean eating patterns, but the key olive oil polyphenols (hydroxytyrosol, oleuropein aglycone, oleocanthal) fall into the gradient-type category — meaning everyone absorbs some, but the range between individuals is clinically significant.
The review also identified something that should give every EVOO clinical trialist pause: most of this inter-individual variability has been poorly characterised in the literature. Trials report means. Regulators require means. But if the response distribution is bimodal or highly skewed, the mean tells you very little about the population-level effect — and almost nothing about the individual.
The Biological Mechanism: It Starts in the Gut
Primary Driver: Gut Microbiota Composition and Activity
Across phenolic sub-classes and across studies, the single most consistent driver of inter-individual bioavailability variability is gut microbiota composition and metabolic activity. This makes biological sense: the majority of polyphenols consumed in food are not absorbed intact in the small intestine. They reach the colon as intact glycosides or esterified forms, where resident bacteria perform the enzymatic biotransformation steps that release aglycones, generate phase II metabolite precursors, and produce the small phenolic acids (like protocatechuic acid from hydroxytyrosol) that actually reach systemic circulation.
A dysbiotic microbiome — depleted in key genera like Bifidobacterium, Lactobacillus, and certain Clostridium clusters — cannot perform these biotransformations efficiently. The result is lower circulating metabolite concentrations, shorter plasma half-lives, and reduced tissue exposure. In contrast, a microbiome rich in phenolic-metabolising species converts a higher fraction of ingested hydroxytyrosol glucosides and oleuropein into bioavailable aglycones and phase II conjugates.
Genetic Polymorphisms (Phase II Enzymes)
UGT (UDP-glucuronosyltransferase) and SULT (sulfotransferase) enzymes conjugate polyphenol aglycones for systemic transport. Variants in UGT1A and SULT1A gene families alter the rate and pattern of this conjugation, producing different metabolite profiles between individuals with different genotypes. This layer of variability is fixed — you can't change your UGT1A1 genotype.
Age, Sex, and Body Composition
Age negatively correlates with polyphenol excretion rates across multiple sub-classes, likely because gut microbiota diversity naturally declines with ageing. Sex differences were also identified for select sub-classes (possibly related to hormonal effects on gut motility and enzyme activity). Elevated BMI is associated with altered microbiome composition and reduced polyphenol biotransformation capacity — meaning those who might benefit most from EVOO's anti-inflammatory effects may also be among the lowest absorbers.
Physical Activity Status
The review identified physical activity as an independent positive modulator of polyphenol excretion. Mechanistically, exercise promotes gut motility, selects for beneficial bacterial species, and upregulates hepatic phase II enzyme expression — all of which increase the processing efficiency for ingested polyphenols. This creates a compounding advantage for physically active individuals: they not only metabolise olive oil polyphenols more efficiently, but they also have lower baseline inflammation against which EVOO's effects act.
The Food Matrix Effect
A lesser-cited but important finding: the food matrix that polyphenols arrive in dramatically affects their bioaccessibility before gut bacteria even get a chance. Some proteins and dietary fibres can bind polyphenols in the upper GI tract, reducing the amount reaching the colon for bacterial biotransformation. For EVOO, the lipid matrix is generally considered advantageous — oleic acid appears to enhance hydroxytyrosol solubilisation and facilitate micelle incorporation, improving small intestinal absorption of the fraction that is hydrolysed prior to the colon.
Advertisement
Context: Why This Paper Reframes a Decade of Olive Oil Research
The bioavailability variability question has been quietly acknowledged in nutrition science for years, but this systematic review is the first to comprehensively map it across 153 studies and multiple phenolic sub-classes. Its specific mention of hydroxytyrosol in the "high/low excretor" category is significant — it means the fundamental pharmacokinetic premise of most EVOO clinical trials (that participants receive equivalent biological doses) is not guaranteed.
This reframes a number of otherwise puzzling results in the literature. The PREDIMED trial, which showed remarkable cardiovascular benefits from a Mediterranean diet supplemented with EVOO, enrolled participants from a Mediterranean region with presumably diverse but broadly healthy microbiomes. Trials in North America or Northern Europe — populations with higher antibiotic use rates, lower baseline fibre intake, and distinct microbial communities — might be expected to show attenuated effects from the same dietary intervention. And indeed, this is broadly what the literature suggests.
It also recontextualises the EU regulatory framework for olive oil polyphenols (Regulation EC 432/2012), which established the health claim at a threshold of 5 mg/day of hydroxytyrosol and its derivatives. That threshold was derived from dose-response data in population studies. But if a substantial fraction of the population absorbs only a fraction of ingested hydroxytyrosol, the "5 mg dietary dose" may translate to very different circulating doses depending on absorber phenotype.
The paper from Del Rio's group builds on earlier work from their own lab and from Manach et al. (who pioneered the bioavailability classification of dietary polyphenols) to provide the most comprehensive treatment of this problem to date. It arrives at a moment when personalised nutrition — using gut microbiome profiling to tailor dietary recommendations — is moving from research promise toward clinical reality.
Practical Takeaways: How to Become a Better Absorber
Choose a genuinely high-phenolic EVOO
If absorber phenotype varies by 5–10× between individuals, a higher-dose starting point matters more. An oil with 700 mg/kg total polyphenols delivering a low absorber 10% of its hydroxytyrosol equivalents still outperforms a 200 mg/kg oil delivering 30% to a high absorber. Lab-certified oils with published polyphenol content are not optional — they're pharmacologically meaningful.
Feed your microbiome — before the EVOO
A diet high in diverse plant fibres (prebiotic substrates) selects for the bacterial species responsible for polyphenol biotransformation. Legumes, whole grains, chicory, and asparagus are particularly potent. The Mediterranean diet is not just about EVOO; it is an ecosystem of synergistic foods that together prime the gut for maximum polyphenol utilisation.
Take EVOO with a meal, not on an empty stomach
The food matrix interaction works in your favour with food present. The presence of dietary fat slows gastric emptying, extends contact time between hydroxytyrosol and the intestinal mucosa, and promotes micelle formation that aids lipid-associated polyphenol absorption in the upper GI. Two tablespoons drizzled over a salad or pasta outperforms the same two tablespoons swallowed neat.
Move regularly — it directly improves polyphenol processing
The systematic review's finding that physical activity is an independent positive modulator of polyphenol excretion means exercise isn't just additive to EVOO's benefits — it amplifies the delivery mechanism. Even moderate walking (150 min/week) is associated with favourable microbiome shifts and upregulation of hepatic phase II enzymes.
Be cautious with antibiotics
Antibiotic courses can temporarily devastate gut microbiota diversity, including the phenolic-metabolising species that convert olive oil polyphenols into bioavailable forms. If you're in a post-antibiotic recovery period, the benefits of your EVOO may be temporarily reduced. Probiotic and prebiotic restoration strategies are warranted.
Limitations: What This Review Cannot Tell Us
- ⚠It is a systematic review, not a meta-analysis.
The paper does not pool quantitative estimates of effect size — it synthesises patterns of variability across heterogeneous study designs. It cannot tell us precisely how much hydroxytyrosol absorption varies between individuals, only that the gradient is clinically meaningful.
- ⚠Hydroxytyrosol-specific data is limited within the review.
The 153 studies span all polyphenol sub-classes. The number of studies specifically examining hydroxytyrosol bioavailability from olive oil (vs. supplemental form) is much smaller. The review's conclusions about hydroxytyrosol high/low excretor phenotypes are well-supported but extrapolate from a sparser evidence base than flavonoids.
- ⚠Causality between microbiome composition and polyphenol absorption is not fully established.
Most of the included studies are observational or pharmacokinetic crossover designs. The causal direction — whether a better microbiome improves polyphenol absorption, or whether polyphenol-rich diets improve the microbiome (which then further improves absorption) — is not definitively established. Likely both are true in a positive feedback loop, but the intervention evidence is incomplete.
- ⚠The clinical relevance of absorber phenotype has not been directly tested in an RCT.
No clinical trial has yet stratified participants by hydroxytyrosol absorber phenotype at randomisation and tested whether the high absorbers show proportionally greater health outcomes. This is the logical next step — and its absence is one of the major knowledge gaps the review explicitly flags.
Our Take: This Is a Strong Paper on an Underappreciated Problem
Favari et al. (2024) is not a flashy paper. It does not announce a new drug target or a stunning clinical breakthrough. What it does — patiently, rigorously, across 153 studies — is make the case that we have been systematically underestimating the complexity of polyphenol pharmacology in humans. And it does so from one of the most credible groups in European nutritional biochemistry, with no declared industry conflicts.
The practical implications for the olive oil space are significant. It explains why EVOO clinical trials show inconsistent results without requiring us to invoke publication bias or shoddy methodology. It also explains why the Mediterranean diet, consumed in its full ecological context (high-fibre plant foods alongside EVOO, regular physical activity, low antibiotic exposure), consistently outperforms isolated EVOO supplementation in trials — the rest of the diet and lifestyle is doing the work of maximising polyphenol bioavailability.
There is a commercial implication here as well. The premium for high-polyphenol EVOO is only justified if the polyphenols actually absorb. For the significant fraction of the population with compromised microbiomes or unfavourable enzyme genotypes, the effective dose delivered may be far lower than the label suggests — not because the oil is substandard, but because the absorption machinery is. The solution is not to abandon high-phenolic oils; it is to invest equally in the gut health that converts those polyphenols into serum-level protection.
Strength rating: ★★★★☆ — A high-quality systematic review addressing a foundational pharmacokinetic question that the field has been avoiding. The absence of quantitative meta-analysis is the primary limitation, but it is appropriate given the heterogeneity of included studies. Highly relevant to anyone interpreting olive oil clinical trial data.
References
- 1. Favari C, Rinaldi de Alvarenga JF, Sánchez-Martínez L, Tosi N, Mignogna C, Cremonini E, Manach C, Bresciani L, Del Rio D, Mena P. Factors driving the inter-individual variability in the metabolism and bioavailability of (poly)phenolic metabolites: A systematic review of human studies. Redox Biol. 2024 May;71:103095. doi: 10.1016/j.redox.2024.103095. PMID: 38428187. PubMed →
- 2. Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L. Polyphenols: food sources and bioavailability. Am J Clin Nutr. 2004;79(5):727–747. PMID: 15113710.
- 3. Visioli F, Rodríguez-Morató J, Ravelli MN, De la Torre R. Olive oil phenolics: biological activity and potential health effects. Eur J Nutr. 2019;58(4):1299–1311. PMID: 30374726.
- 4. Commission Regulation (EU) No 432/2012. Health claim on olive oil polyphenols: EU authorisation framework. Official Journal of the European Union, 2012.
- 5. Estruch R et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts (PREDIMED). N Engl J Med. 2018;378(25):e34. PMID: 29897866.
Get the Most from Your EVOO
Bioavailability starts with a genuinely high-phenolic oil. See our ranked list of lab-tested, certified EVOOs with the polyphenol content to matter — even for low absorbers.
See Top-Ranked EVOOs →